Cargando…

Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021

Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Azzoug, Chana, Nuémi, Gilles, Menu, Didier, De Maistre, Emmanuel, Boulin, Mathieu, Putot, Alain, Manckoundia, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859400/
https://www.ncbi.nlm.nih.gov/pubmed/36674204
http://dx.doi.org/10.3390/ijerph20021448
_version_ 1784874345735127040
author Azzoug, Chana
Nuémi, Gilles
Menu, Didier
De Maistre, Emmanuel
Boulin, Mathieu
Putot, Alain
Manckoundia, Patrick
author_facet Azzoug, Chana
Nuémi, Gilles
Menu, Didier
De Maistre, Emmanuel
Boulin, Mathieu
Putot, Alain
Manckoundia, Patrick
author_sort Azzoug, Chana
collection PubMed
description Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualité Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) (p < 0.001), fewer RCD (91.47% vs. 93.68%) (p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) (p < 0.001), severe heart failure (56.50% vs. 68.03%) (p < 0.001), and severe kidney diseases (1.38% vs. 3.59%) (p < 0.001), but there were more subjects with Alzheimer’s disease (7.49% vs. 4.31%) (p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) (p < 0.001) and fibrates (2.32% vs. 3.88%) (p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) (p = 0.006) and antirheumatics (1.60% vs. 0.65%) (p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time.
format Online
Article
Text
id pubmed-9859400
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98594002023-01-21 Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021 Azzoug, Chana Nuémi, Gilles Menu, Didier De Maistre, Emmanuel Boulin, Mathieu Putot, Alain Manckoundia, Patrick Int J Environ Res Public Health Article Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualité Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) (p < 0.001), fewer RCD (91.47% vs. 93.68%) (p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) (p < 0.001), severe heart failure (56.50% vs. 68.03%) (p < 0.001), and severe kidney diseases (1.38% vs. 3.59%) (p < 0.001), but there were more subjects with Alzheimer’s disease (7.49% vs. 4.31%) (p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) (p < 0.001) and fibrates (2.32% vs. 3.88%) (p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) (p = 0.006) and antirheumatics (1.60% vs. 0.65%) (p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time. MDPI 2023-01-13 /pmc/articles/PMC9859400/ /pubmed/36674204 http://dx.doi.org/10.3390/ijerph20021448 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Azzoug, Chana
Nuémi, Gilles
Menu, Didier
De Maistre, Emmanuel
Boulin, Mathieu
Putot, Alain
Manckoundia, Patrick
Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
title Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
title_full Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
title_fullStr Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
title_full_unstemmed Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
title_short Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021
title_sort direct oral anticoagulants versus vitamin k antagonists in individuals aged 80 years and older: an overview in 2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859400/
https://www.ncbi.nlm.nih.gov/pubmed/36674204
http://dx.doi.org/10.3390/ijerph20021448
work_keys_str_mv AT azzougchana directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021
AT nuemigilles directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021
AT menudidier directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021
AT demaistreemmanuel directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021
AT boulinmathieu directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021
AT putotalain directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021
AT manckoundiapatrick directoralanticoagulantsversusvitaminkantagonistsinindividualsaged80yearsandolderanoverviewin2021